ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0264

A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis
Abstract Number: 0265

Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing
Abstract Number: 0266

E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Abstract Number: 0267

Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists
Abstract Number: 0268

Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis
Abstract Number: 0269

Acute Kidney Injury and Plasma Cell-Rich Acute Interstitial Nephritis in VEXAS Syndrome: An Under-recognized Disease Feature
Abstract Number: 0270

Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety
Abstract Number: 0271

Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients
Abstract Number: 0272

Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Abstract Number: 0273

Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement
Abstract Number: 0274

A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab
Abstract Number: 0275

No Cumulative Effect of Infection Rates in Children Receiving Long-term Canakinumab Treatment in Autoinflammatory Periodic Fever Syndromes − Data from the RELIANCE Registry
Abstract Number: 0276

Disease Control in Patients with Monogenetic Autoinflammatory Diseases Under Canakinumab Treatment – Comparison of 30 Months Interim Data from the RELIANCE Registry
Abstract Number: 0277

Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Abstract Number: 0278

NOD2 Genotyping Landscape in Yao Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].